drugset / Trial / NCT05743907

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT05743907

Phase 4 Completed 231 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control

Timeline

Start
2023-04-25
Primary completion
2025-03-10
Completion
2025-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-2811 Unknown
Comparator Forxiga Unknown

Indications